Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

Not Applicable

Not yet recruiting

• Conditions: Amyotrophic Lateral Sclerosis; Terazosin; Adenosine Triphosphate Activities
• Interventions: Drug: Terazosine

• Registration Number: NCT07224269
• Lead Sponsor: University of Iowa

Brief Summary

This will be a single center, open label pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whether TZ increases adenosine triphosphate (ATP) levels in ALS. We will measure adverse outcomes, safety, and tolerability of taking TZ. Procedures include blood draws, spirometry, lumbar punctures, fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, questionnaires, and physical examinations. TZ will be titrated up to 5 mg PO daily. This is a pilot study and is not powered to assess efficacy of this medication. Our hope is that this study will guide future studies of this (and similar) medications for the disease modification of ALS. This study also aims to learn more about how patients produce and use energy and if TZ can help to reverse energy deficits that appear in ALS.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-10
• Study First Submitted: 2025-10-31
• Study First Submitted QC: 2025-10-31
• Last Update Submitted: 2025-10-31
• Study First Posted: 2025-11-04
• Last Update Posted: 2025-11-04
• Study Start: 2025-11-17
• Primary Completion: 2026-07-01
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Terazosin	Terazosine	-

Primary Outcome Measures

Name	Time	Method
Change in ATP levels	Baseline and 12 weeks	Mean percent change from baseline to 12 weeks in whole-blood ATP and brain glycolytic rate using FDG-PET imaging

Trial Locations

Locations (1)

University of Iowa Health Care; 🇺🇸 Iowa City, Iowa, United States